{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"13"}],"units":"Participants"}],"description":"DOR was defined as the date of first complete response (CR) achieved to the date of first evidence of recurrence or progression or death, using cystoscopy, centrally read bladder biopsy and urine cytology, and imaging, if available. Complete response was defined as having a negative cystoscopy and negative (including atypical) centrally assessed urine cytology, or positive cystoscopy with biopsy-proven benign or low-grade NMIBC and negative (including atypical) centrally assessed cytology at any time point. Number of participants with at least 12 months duration of response were reported.","groups":[{"description":"Participants with CIS with or without papillary disease, received TAR-200 intravesically every 3 weeks (Q3W) from Week 0 for the first 24 weeks, followed by every 12 weeks (Q12W) dosing through Week 99 in combination with cetrelimab 360 milligrams (mg) intravenously (IV) Q3W from Week 0 through Week 78. TAR-200 was inserted intravesically via the urinary placement catheter (UPC).","id":"OG000","title":"Cohort 1: TAR-200 + Cetrelimab (CIS With or Without Papillary Disease)"},{"description":"Participants with CIS with or without papillary disease, received TAR-200 intravesically Q3W from Week 0 for the first 24 weeks, followed by Q12W dosing through Week 99. TAR-200 was inserted intravesically via UPC.","id":"OG001","title":"Cohort 2: TAR-200 Monotherapy (CIS With or Without Papillary Disease)"},{"description":"Participants with CIS with or without papillary disease, received cetrelimab 360 mg IV Q3W from Week 0 through Week 78.","id":"OG002","title":"Cohort 3: Cetrelimab IV Monotherapy (CIS With or Without Papillary Disease)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"FAS included all enrolled participants who received at least 1 dose of study treatment. Here \"N\" (overall number of participants analyzed) signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From onset of first CR up to clinical cut-off date 3rd July 2025 (up to 47.3 months)","title":"Cohorts 1, 2, and 3: Number of Participants With at Least 12 Months Duration of Response","type":"SECONDARY","unitOfMeasure":"Participants"}